Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa for presurgical autologous blood donation
NCT00270114Phase 3Completed
- Sponsor
- Johnson & Johnson
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, open-label trial of epoetin alfa in anemia (4 arms), sponsored by Johnson & Johnson. Primary endpoints: Number of self-donated units of blood, Total volume of red blood cells donated and 1 more. Status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00270114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270114.